At a glance
Drug class
Dual GIP and GLP-1 receptor agonist
How it's taken
Once-weekly subcutaneous injection, titrated gradually
Dispensed by
Licensed US pharmacy partner
Indication
Prescribed by a licensed provider for weight management or glycemic control in eligible adults.
- Acts on two receptors, not one
- Once-weekly dosing
- Gradual titration schedule
- Provider-supervised throughout
Important safety information
This is a summary, not the full prescribing information. Review the complete label with your provider before starting treatment.
- Contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
- Not for use during pregnancy, while breastfeeding, or while trying to conceive.
- Most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation.
How care works
Check eligibility
A fast, mobile-friendly quiz screens for clinical fit and state licensing.
Choose your plan
Transparent monthly pricing. No hidden fees. Cancel or pause anytime.
Clinical intake
Share your history securely. A licensed US provider reviews asynchronously.
Ongoing care
Medication when appropriate, refills, messaging, and progress tracking.
Product imagery is illustrative and does not depict actual packaging or the specific device you would receive. This page is informational and is not medical advice. Tirzepatide is available by prescription only. A licensed US provider determines whether treatment is appropriate after reviewing your medical history; a prescription is never guaranteed. Pricing shown does not constitute an offer and may vary by pharmacy and dose.